Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: Maintenance is necessary to sustain response

Leukemia and Lymphoma

Volumn 40, Issue 1-2, 2000, Pages 141-147

  Siakantaris, M P ^a   Angelopoulou, M K ^a   Vassilakopoulos, T P ^a   Dimopoulou, M N ^a   Kontopidou, F N ^a   Pangalis, G A ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Anaemia of B cell lymphoproliferative disorders; B CLL; Disease related anaemia; Human recombinant erythropoietin; Small cell lymphoma

Indexed keywords

CHLORAMBUCIL; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LEUKEMIA; BONE MARROW; CANCER INFILTRATION; CANCER RECURRENCE; CANCER STAGING; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SPLENOMEGALY; SURVIVAL;

EID: 0035126147     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009054891     Document Type: Article

References (35)

1. Malignant disorders of small lymphocytes. Small lymphocytic lymphoma, lymphoplasmacytic lymphoma and chronic lymphocytic leukemia: Their clinical and laboratory relationship
2. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, lymphoplasmacytic lymphoma and Waldenstrom's macroglobulinemia: A clinical, morphologic and biologic spectrum of similar disorders
3. Iron deficiency, pathogenesis, clinical aspects, therapy
4. Hemolytic anemia and acute blood loss
5. Clinical spectrum of auto-immune haemolytic anaemia in patients with chronic lymphocytic leukaemia
6. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia and autoimmune thrombocytopenia
7. Progress in understanding the pathogenesis of the anemia of chronic disease
8. The anemia of chronic disease
9. The role of cytokines in the supportive care of oncology patients
10. Impact of therapy with epoetin alfa on clinical outcome in patients with non-myeloid malignancies during cancer chmotherapy in community oncology practice
11. Erythropoietin treatment of anemia associated with multiple myeloma
12. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration
13. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin
14. Prolonged intermittent chlorambucil administration in B-chronic lymphocytic leukemia: Experience from a Single Hematology Unit
15. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
16. Frequency and significance of anemia in non-Hodgkin's lymphoma patients
17. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis
18. Erythropoietin and the anemia of cancer
19. The anemia of chronic disorders: Studies of marrow regulation and iron metabolism
20. Erythropoiesis, erythropoietin and iron
21. Serum erythropoietin values and serum iron status during chemotherapy for leukemia
22. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
23. Special report: Transfusion risks
24. Guidelines for the use of recombinant human erythropoietin
25. Downstaging Rai stage III B-chronic lymphocytic leukemia (B-CLL) patients by the successful administration of recombinant human erythropoietin (r-HuEPO) could change the natural history of the disease
26. Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin
27. Factors influencing quality of life in cancer patients: Anemia and fatigue
28. Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy
29. Once-weekly dosing of epoetin alfa is similar to three times weekly dosing in increasing hemoglobin and quality of life
30. Prediction of response to erythropoietin treatment in chronic anemia of cancer
31. Prediction of response of optimize outcome of treatment with erythropoietin
32. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial
33. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anaemia: Results of double-blind and open-label follow-up studies
34. Epoetin alfa and high-dose chemotherapy
35. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy advances hemopoietic progenitor moboilization